🔗 Share this article

While the US continues making unprecedented revisions to its vaccine schedules, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by questioning COVID-19 vaccinations in the global health crisis and has zeroed in on possible deaths following Covid vaccination in her brief tenure at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Program

Agency leaders had intended to announce radical changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US at odds with a large portion of the world with little proof for improved outcomes. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing some childhood immunization guidelines in the US so as to align more similar to the Danish model, a society with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than drug regulation.

Questions Over Qualifications

The appointee has no apparent experience in pharmaceutical research, oversight or management, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the CDER, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She is not an expert in drug approvals.”

Previous commissioners of the center would “understand legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who ran the center have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“The public just focuses on the new drug program, but the generic program clears numerous generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be managed,” Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant leadership aspect to the role, which manages more than 5,000 staff members. “It is a huge administrative position, if you do it right,” she concluded.

Official Statement and Controversial Programs

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a press secretary responded that the “questions are based on incorrect presumptions”.

“Her experience matches the functions of her position,” the representative said, pointing to the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's recently launched expedited review system, a contentious rapid medication authorization process that apparently concerned her predecessors. “By what process are these drugs being picked for this fast-track system? Who takes the calls?” Dr. Howard asked. “There’s a lot of confidentiality going on at the FDA right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, with the exception of shots.”

Public Past Work on Immunizations

With vaccines, Høeg has a more established, if concerning, track record, some experts have noted. She released a study using unconfirmed crowd-sourced reports to estimate the frequency of myocarditis following Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming government featured revising guidelines for new vaccines and ending “non-essential” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of preventing teenage boys from receiving COVID-19 vaccines.

“She’s an thorough true believer who starts off with her preconceived notions and tailors the evidence to accommodate the evidence in a highly misleading, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow contrarians, {like|